HIV Archives – Page 12 of 90 – Treatment Action Group

TAG Comments on NIST’s Proposed Rulemaking Changes

April 4, 2021
Dorrit Walsh

TAG submitted comments in response to the National Institute of Standards and Technology's (NIST) proposed change to rulemaking, strongly opposing amendments to remove crucial public health safeguards from the Bayh-Dole Act. March-in rights and other provisions to hold manufacturers accountable when federally funded inventions are exorbitantly priced and are critically important to public health and the right to science.

Civil Society Letter to Donors, Countries, and Health Actors to Improve Access to GeneXpert and Other Diagnostics

April 1, 2021
Dorrit Walsh

TAG led an open letter appealing to donors, countries, and health actors to improve access to GeneXpert and other diagnostics for COVID-19, TB, HIV, HBV, HCV, and other diseases by applying collective leverage in negotiations with Cepheid for lower prices and sufficient volumes; establishing cost-of-goods-sold (COGS)-plus and volume-based pricing for diagnostics as a global norm; and increasing investments in alternative rapid molecular tests to promote competition and improve access.

How Lessons Learned from the HIV Epidemic Can Inform Efforts to Address the COVID-19 Pandemic Through a Racial Equity Lens

March 5, 2021
Dorrit Walsh

Join us on March 15, 2021 at 4:00 p.m. EST for this free webinar, which will discuss a variety of issues concerning disenfranchised communities being disproportionately affected by COVID-19.

Civil Society Letter to Cepheid Requesting Lower Prices for Xpert SARS-CoV-2 Tests and Increased Volumes Distributed to LMICs

February 25, 2021
Dorrit Walsh

February 25, 2021 — TAG signed onto this letter requesting that diagnostics company Cepheid increase access to Xpert SARS-CoV-2 tests in low- and middle-income countries (LMICs) by committing a greater proportion of its SARS-CoV-2 test manufacturing capacity to LMICs and…

Image for the 2021 Community HIV Cure Research Workshop

Pre- and Post-CROI Community HIV Cure Research Workshop

February 17, 2021
Dorrit Walsh

The 2021 Community HIV Cure Research Workshop will take place virtually this year due to the ongoing COVID-19 pandemic. The workshop sessions will be held on Thursday, March 4 and Friday, March 5, 2021 (right before CROI 2021), and then on Tuesday, March 16, 2021 (after the conference).

TAG/COVID-19 Prevention Network: HIV, COVID-19 Outcomes and Implications for COVID-19 Vaccines

January 26, 2021
Dorrit Walsh

Join TAG and COVID-19 Prevention Network (CoVPN) On Tuesday February 2nd at 4pm ET / 1pm PT, at a webinar for community advocates on COVID-19 outcomes in people living with HIV and implications for COVID-19 vaccines.

Good COPs or Bad COPs: Promoting Interventions for Co-Infections and Advanced HIV Disease in 2021 PEPFAR Country Operational Plans (COPs)

January 21, 2021
Dorrit Walsh

On January 21, 2021, Treatment Action Group (TAG), Health GAP, and MSF Access Campaign presented this webinar on how to engage in PEPFAR COPs advocacy and promote the prioritization of interventions that address co-infections and advanced HIV disease.

2020 TAG Update

December 11, 2020
Dorrit Walsh

As we look forward to an end of an extremely challenging year—and past four years—we reflect on the remarkable resilience and impact of TAG, even and especially in these dark times.

TAG Applauds Dr. Demetre Daskalakis’ Appointment as CDC Director of the Division of HIV/AIDS Prevention: NYC’s Loss is America’s Gain

November 19, 2020
Dorrit Walsh

Treatment Action Group applauds the appointment of Dr. Demetre Daskalakis to helm the U.S. Centers for Disease Control and Prevention (CDC)’s Division of HIV/AIDS Prevention (DHAP). We can think of no better public health practitioner to embody true innovation and disrupt the status quo in our national HIV prevention response.

Treatment Action Group Statement on Early Findings from HPTN 084

November 12, 2020
Dorrit Walsh

Treatment Action Group welcomes the announcement that the phase 3 HPTN 084 trial proved that intramuscular injections of ViiV’s long acting cabotegravir (CAB-LA) every eight weeks were superior to daily oral TDF/FTC pre-exposure prophylaxis (PrEP) in preventing new HIV infections in cisgender women in sub-Saharan Africa.